MDS Tourette Syndrome Study Group found no compelling evidence to make general clinical recommendations on complementary medicine for TS. Rather, they advise knowledge gap transparency when engaging patients about specific treatments. https://loom.ly/mMBjYSw

Could DBS reshape the brain beyond symptom control? Neuroimaging shows: -Increased STN activity -Mixed connectivity shifts in motor & non-motor networks -Hippocampal atrophy—aging or DBS effect?What does this mean for long-term cognition? What are the implication? Read more: https://loom.ly/AmBkTOs

Menstrual cycle & pregnancy matter in Parkinsons! 60% of women with early-onset PD report perimenstrual worsening; 40% experience symptom changes during pregnancy/postpartum. An unmet need for tailored guidelines! An unmet need for tailored guidelines! https://loom.ly/Gcn02nA

New MDCP Pearl: Orthostatic Tremor Is Evoked by Muscle Load Without the Need for Orthostatic Position https://loom.ly/fLM3XHw

Deep Brain Stimulation isn’t just for motor symptoms—what about autonomic dysfunction in Parkinsons? This scoping review maps evidence across GI, cardiovascular, urinary, thermoregulatory & respiratory domains. Read more: https://loom.ly/TdaWKG0

Functional gait disorder is complex—6 existing phenotypic frameworks fail to fully capture its heterogeneity. Fung (2016) and Baik & Lang (2007) classify most cases, but inter-rater reliability remains low. The Future? Data-driven, objective tools for better classification. https://loom.ly/3NNoG8I

Staged bilateral focused ultrasound for essential tremor shows significant tremor control, but a new study highlights a possible higher rate of patient reported adverse effects. https://loom.ly/JSBbEkk

New MDCP Pearl: Functional Head Tremor: Contrasting Features with Other Tremor Etiologies. https://doi.org/10.1002/mdc3.70205

Freezing of gait in Parkinson’s can worsen dramatically in low-light conditions—72% frozen time vs. 40% in daylight. Lighting isn’t just environmental, it’s therapeutic. Consider illumination as part of your fall prevention strategy! https://loom.ly/Z53Rdl8

Several tools to measure PD symptom severity require updating to address past limitations or new developments in clinimetrics and wearable technology, per COA Scientific Evaluation Committee’s state-of-the-art review of clinical outcome assessments. https://loom.ly/R_ia5KY

LABS-PD cohort data at 5 years post diagnosis linked specific prognoses to "tremor predominant” and “motor complications” subtypes. Further subtype stratification may guide prognostication, inform trial design, and support tailored care planning. https://loom.ly/WMoDRd8

Follow-up analysis of predictive value for initiation of dopaminergic therapy in early PD led MDS’s #COA Program to conclude that a subset of 11 patient-reported items from the MDS-UPDRS actually outperformed the full 20-item scale. https://loom.ly/Uxk8CLQ#COA

New MDCP Pearl: Differential Effects of Levodopa and Stimulation on Post-Surgery Freezing of Gait in Subthalamic Nucleus Deep Brain Stimulation Parkinson's Disease Patients: A Clinical and Kinematic Analysis. https://loom.ly/Twv6N80

Long-term follow-up of patients with mass social media–induced functional tic-like behaviors shows: -76% improved or remitted -Better outcomes with early diagnosis, younger age, male sex, fewer comorbidities, no depression Early recognition & psychiatric care are key. https://loom.ly/L3M8c8o

This MDS Task Force review of evidence-based wellness interventions for PD recommends a proactive, practical, multidisciplinary approach. https://loom.ly/4oNw7ak

GI symptoms in #Parkinsons are common—but often overlooked. A novel interdisciplinary PDGI clinic model improves diagnosis, treatment & QoL by integrating neuro + gastro care. A scalable blueprint for tackling nonmotor symptoms! https://loom.ly/99HkQgo

In PD, cognitive decline remains a major challenge. This new study shows that elevated CSF DOPA decarboxylase (DDC) levels predict cognitive deterioration independent of dopaminergic therapy. Could DDC be your next prognostic biomarker? https://loom.ly/btGIhxc

Meta-analysis shows botulinum toxin offers moderate, patient-reported benefit for upper limb tremor (ET & DT), with no consistent effect on clinician-rated scores or grip strength. No clear “best” injection strategy yet—more trials needed! https://loom.ly/y__Uvqg

Slow-motion videography reveals “air writing” before pen hits paper in writer’s cramp—capturing subtle motor signs missed at normal speed. A simple smartphone tool, big clinical insights! https://loom.ly/RQPqYVQ

Balance problems in Huntington’s disease start early—even before motor symptoms appear! Using a simple body sway test, researchers tracked progressive balance loss across all stages. Early detection = earlier intervention! https://loom.ly/7CZFC68

New MDCP Pearl: The Impact of Deep Brain Stimulation of the Subthalamic Nucleus on Sleep–Wake Function and Circadian Rhythms in Patients with Parkinson's Disease. https://loom.ly/UX6YW_0

Systematic reprogramming of chronic STN-DBS in Parkinson’s boosted motor scores by 25%—even years after implantation—without upping meds. Don’t settle for suboptimal DBS: re-tune for real gains! https://loom.ly/g1QYa4M

Mobile devices are now the go-to for telemedicine in movement disorders—used in 88% of video visits! Age <60 is the biggest predictor. Time to optimize care and research for the mobile-first era! https://loom.ly/3dA6LMU

🧠 Vim DBS for dystonic head tremor? Long-term data in 18 patients shows sustained benefit in this phenotype. A compelling case for thalamic (rather than GPi) targeting when head tremor is dominant! https://loom.ly/Ciee65w

Which is best, one side or two? A Systematic Review of Deep Brain Stimulation Approaches in PD and Essential Tremor. https://loom.ly/dT7cWGA

Regional variations in PSP prevalence and phenotype highlight global differences in genetic predispositions, environmental risk factors, and healthcare infrastructure. Fortunately, diagnostic accuracy has improved with the adoption of updated MDS-PSP criteria. https://loom.ly/4PtQtz4

Vestibular signs and symptoms are common in Parkinson’s but often overlooked. This review highlights the need for better, standardized assessment tools. https://loom.ly/KKX1Tz0

New MDCP Clinical Pearl: Sustained Therapeutic Benefits Using Image-Guided Programming at Activation of Deep Brain Stimulation for Parkinson's Disease https://loom.ly/ry4ZUE8

Adopting Serious Illness Conversation (SIC) framework can help neurology clinicans improve the journey of indivials and care partners with atypical parkinsonian disorders (APD) today. https://loom.ly/ujT7RDo

Glymphatic dysfunction is a key feature of Parkinson’s disease as assessed by multiple MRI markers and is closely tied to motor symptoms. These findings may open new paths for diagnosis and treatment. https://loom.ly/YZCtAMk

How are skin punch biopsies for phosphorylated alpha-synuclein being used in clinical practice? How do the results affect treatment and management? This new article from MDCP explores these questions. https://loom.ly/DRqfKT8

New FOSAPO study on switching from apomorphine to foslevodopa/foscarbidopa in advanced PD: Improved motor outcomes, good tolerability, and watch for DAWS! https://loom.ly/-4c-YWo

Even in PwP with advanced disease, cognitive impairment, psychosis, or prior device aided therapy failure, foslevodopa/foscarbidopa infusion may be a well-tolerated treatment option. https://loom.ly/jIMGsoY

Video - and Home-Based Training Programs for People with Hereditary Ataxia - does it make any difference? Read on to find out! https://loom.ly/b0A-JCA

Levodopa-Carbidopa Intestinal Gel monotherapy in PD is a viable option for many patients, with beneficial safety and both motor and non-motor efficacy outcomes. https://loom.ly/hIDIcJQ

New MDCP Clinical Pearl: Clinical and Biomechanical Factors in the Sit-to-Stand Decline in Parkinson's Disease https://doi.org/10.1002/mdc3.70122

AI-based handwriting analysis- a useful biomarker in PD? Read on to find out! https://loom.ly/TS_auJM

New MDCP Clinical Pearl: Speech Differences between Multiple System Atrophy and Parkinson's Disease. https://doi.org/10.1002/mdc3.70094